ACIRNA Therapeutics (formerly Chimeron Bio) receives NIH (NCI) Innovative Concept Award for mRNA cancer vaccine development
← Back to news April 16, 2024 ACIRNA Therapeutics (formerly Chimeron Bio) receives NIH (NCI) Innovative Concept Award for mRNA cancer vaccine development Chimeron Bio is now ACIRNA Therapeutics. This announcement was originally issued under the Chimeron Bio name. Philadelphia, PA: Chimeron Bio (now ACIRNA Therapeutics), a Philadelphia-headquartered biotech company, has received a 2024 National […]
ACIRNA Therapeutics (formerly Chimeron Bio) recognized by MilliporeSigma as a finalist in the Advance Biotech Grant Award
← Back to news June 6, 2023 ACIRNA Therapeutics (formerly Chimeron Bio) recognized by MilliporeSigma as a finalist in the Advance Biotech Grant Award Chimeron Bio is now ACIRNA Therapeutics. This announcement was originally issued under the Chimeron Bio name. Philadelphia, PA: Chimeron Bio (now ACIRNA Therapeutics), a next-generation RNA company developing self-amplifying RNA (saRNA) […]
ACIRNA Therapeutics (formerly Chimeron Bio) appoints Antonin de Fougerolles to its Board of Directors
← Back to news December 15, 2022 ACIRNA Therapeutics (formerly Chimeron Bio) appoints Antonin de Fougerolles to its Board of Directors Chimeron Bio is now ACIRNA Therapeutics. This announcement was originally issued under the Chimeron Bio name. Philadelphia, PA: Chimeron Bio (now ACIRNA Therapeutics), an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed […]